Anbio Biotechnology (NNNN) Receivables (2023 - 2025)

Anbio Biotechnology's Receivables history runs 3 years deep, the most recent figure standing at $3.7 million for Q4 2025.

• In Q4 2025, Receivables rose 243.44% year-over-year to $3.7 million; the TTM figure through Dec 2025 stood at $3.7 million (up 243.44% YoY), while the FY2025 annual figure was $3.7 million, up 243.44% from the prior year.
• Receivables was $3.7 million for Q4 2025 at Anbio Biotechnology, down from $3716.4 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $3716.4 billion in Q2 2025 to a low of $1.1 million in Q4 2024.
• Historically, Receivables has averaged $929.1 billion across 3 years, with a median of $2.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables plunged 43.51% in 2024, then soared 243.44% in 2025.
• A 3-year view of Receivables shows it stood at $1.9 million in 2023, then sank by 43.51% to $1.1 million in 2024, then jumped by 243.44% to $3.7 million in 2025.
• The last three Receivables figures came in at $3.7 million (Q4 2025), $3716.4 billion (Q2 2025), and $1.1 million (Q4 2024), per Business Quant data.